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ABSTRACT
Aim To investigate the characteristics of meticillin-resistant S. au-
reus (MRSA), extended-spectrum (ESBL), and plasmid-mediated 
AmpC beta-lactamase producing Gram-negative bacteria causing 
skin and soft tissue infections (SSTIs) in hospital and outpatient 
settings of Zenica-Doboj Canton, Bosnia and Herzegovina.
Methods Antibiotic susceptibility was determined by disc-diffusi-
on and broth microdillution methods according to CLSI guideli-
nes. MecA gene was detected by PCR, and genetic characteriza-
tion of MRSA was performed using spa-typing and the algorithm 
based upon repeat patterns (BURP). Double-disk-synergy test was 
used to screen for ESBLs. PCR was used to detect blaESBL alleles. 
Genetic relatedness of the strains was tested by PFGE.
Results Seventeen in-patients with MRSA, 13 with ESBL-produ-
cing Gram-negative bacteria and three patients co-infected with 
both, were detected. Five MRSA and 16 ESBL-producing Gram-
negative bacteria were found in outpatient samples. Klebsiella 
spp. was isolated in 11 in- and seven outpatients. MLST CC152 
was the most prevalent MRSA. Seven (38.9%) Klebsiella spp. yi-
elded amplicons with primers specific for SHV, TEM-1 and CTX-
M group 1 β-lactamases. Eight K. pneumonia (44.4%)  and 16 
(64%) MRSA (including the in- and outpatient) strains were clo-
nally related. 
Conclusion The presence of MRSA and ESBL-producing organi-
sms causing SSTIs in the community poses a substantial concern, 
due to the high morbidity and mortality associated with possible 
consequent hospital infections. 
Key words: surgical wound infections, CTX-M beta-lactamase, 
MLST CC152, antibiotic resistance
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INTRODUCTION
According to Edelsberg’s classification skin and 
soft tissue infections (SSTIs) include eighteen 
types of infections (1). With regard to predomi-
nanted (microbial etiology) pathogens and risk of 
mortality (severity of local and systemic signs) 
there are superficial SSTIs caused by Staphylo-
coccus aureus or Streptococcus pyogenes, dee-
per or healthcare-associated infections caused by 
anaerobic or gram-negative organisms,  and gan-
grenous or necrotizing infections (or “often fatal 
infections”) (1,2). The practice guidelines of the 
Infectious Diseases Society of America (IDSA) 
for the diagnosis and management of skin and 
soft tissue infections (3) classifies SSTIs into five 
categories, including superficial, uncomplicated 
infection (impetigo, erysipelas and cellulitis), ne-
crotizing infection, infections associated with bi-
tes and animal contact, surgical site infections and 
infections in the immunocompromised host. The 
purpose of all SSTI definitions is to  develop the 
useful guidelines for the clinical management and 
treatment options for patients with SSTIs (1,3). 
The annual frequency of visits to physicians’ offi-
ces for SSTIs have an increasing trend (4). The 
predominant pathogens associated with SSTIs in 
hospitalized patients include S. aureus (ranked first 
in all geographical regions), Pseudomonas aerugi-
nosa, Escherichia coli and Enterococcus spp. (5).
Methicillin-resistant Staphylococcus aure-
us (MRSA) causes many infections, but most 
frequently SSTIs, such as cutaneous abscesses, 
furuncles and cellulitis. Thus, the prevalence of 
these infections has increased dramatically (6). 
Risk factors for MRSA SSTIs include the presen-
ce of an abscess, previous MRSA colonization/
infection, antibiotic prescriptions within 8 weeks, 
diabetes mellitus and hospital admission within 
the preceding year (6).
Extended-spectrum beta-lactamase (ESBL) pro-
duction is one of the main mechanisms of resi-
stance to beta-lactam antibiotics in Enterobacte-
riaceae, so the therapeutic choices in infections 
caused by such strains are limited (7,8).  Most 
ESBLs belong to SHV and TEM family, but 
recently a new family of ESBLs with predo-
minant activity against cefotaxime (CTX-M 
β-lactamase) has been reported (8). In contrast to 
TEM or SHV-ESBLs, CTX-M β-lactamases are 
native ESBLs and are derived from the chromo-
somal β-lactamases of the genus Kluyvera (9). 
In many countries CTX-M β-lactamases are the 
most prevalent type of ESBLs (9,10). Plasmid-
mediated AmpC β-lactamases are derived from 
chromosomal ampC genes of the family Entero-
bacteriaceae. AmpC enzymes encoded by both 
chromosomal and plasmid genes are also evol-
ving to hydrolyze broad-spectrum cephalospo-
rins more efficiently (11).
Since most skin and soft tissue infections in 
outpatient settings are treated with empiric an-
timicrobial therapy, it is very important to esti-
mate the prevalence of causative agents associa-
ted with skin and soft tissue infections, as well 
as their antimicrobial resistance patterns and 
mechanisms (3-5) . 
The aim of this study was to determine prevalen-
ce and molecular epidemiology of SSTIs caused 
by MRSA, ESBL- and plasmid-mediated AmpC-
producing β-lactamase Gram-negative bacteria 
in the in- and outpatient settings in Zenica-Doboj 
Canton, Bosnia and Herzegovina (B&H).
MATERIALS AND METHODS
Setting, bacterial isolates and study design
The Cantonal Hospital Zenica, B&H, is a 849-
bed tertiary level hospital admitting about 25.000 
patients/year, with 240.000 patient days, and co-
vers a population of 331.229 in Zenica-Doboj 
Canton, B&H. 
All consecutive, non-duplicate strains identified 
as MRSA and/or ESBL- or plasmid-mediated 
AmpC β-lactamase-producing Gram-negative 
bacteria obtained from SSTIs of the in- and out-
patients during the period December 2009–May 
2010 were analyzed. The SSTIs comprise sur-
gical wound infections (SWIs) (postoperation 
and postraumatic wound infection) and ‘’other 
SSTIs’’ (oSSTIs) (including furuncles/abscesses, 
cellulitis, folliculitis) documented by the clinical 
provider/physician).
Clinical and epidemiological data recorded for 
the patients involved in the study included: age, 
gender, occupation, place of residence at admi-
ssion to the hospital (e.g. at home, other hospi-
tal, nursing home), contact with person(s) with 
history of hospitalization in the past 12 months, 
hospital department, antibiotic usage in the past 
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four months, isolated causative agent (MRSA 
and/or ESBL or plasmid-mediated AmpC 
β-lactamase-producing Gram–negative bacteria).
An institutional review board approval had been 
obtained from the Ethics Committee in the Canto-
nal Hospital of Zenica prior to the initiation of the 
study, and all the participants read and signed infor-
med consents about the purpose of the study (par-
ticipation was voluntary and anonymous) as well. 
Identification of MRSA and susceptibility testing
Staphylococcus aureus isolates were identified 
according to standard microbiological methods. 
The strains were tested for oxacillin and cefoxitin 
sensitivity/resistance by disk-diffusion method at 
Mueller-Hinton (MH) agar (Oxoid, Basingstoke, 
UK) (growth zone inhibition around 1 µg and 30 
µg oxacillin and cefoxitin disk, respectively) in 
accordance with CLSI (Clinical Laboratory Stan-
dards) guidelines (12).
All S. aureus isolates were analyzed for the pre-
sence of the S. aureus-specific femA gene as well 
as the MRSA-specific mecA gene using a multi-
plex real-time PCR assay (13).
The disc diffusion method using Mueller-Hinton 
agar (Oxoid, Besingstoke, UK) was used to test 
susceptibility to  11 antimicrobials (Oxoid, Ba-
singstoke, UK): mupirocin, MUP (200 µg), imi-
penem, IPM (10 µg), erythromycin, ERY (15 µg), 
vancomycin, VAN (30 µg),  gentamicin, GEN (10 
µg), amikacin, AMK (30 µg), ciprofloxacin, CIP 
(5 µg),  clindamycin, CLI (2 µg), trimethoprim/
sulfamethoxazole, SXT (25  µg), chlorampheni-
col, CHL  (30 µg), and rifampicin, RIF  (5 µg). 
The susceptibility testing results were interpreted 
according to CLSI (12). Staphylococcus aureus 
ATCC 25923 control strain was used for quality 
control. Multidrug resistance (MDR) was defined 
as resistance to three or more groups of antibiotics.
Susceptibility testing of ESBL and AmpC produc-
ing bacteria
The susceptibility testing to cefuroxime (CXM), 
ceftazidime (CAZ), ceftriaxone (CRO), cefotaxi-
me (CTX), cefoxitin (FOX), tazobactam (TZP), 
cefepime (FEP), gentamicin (FEP), ciprofloxacin 
(CIP), and piperacillin (PIP) was performed by 
a twofold microdilution technique according to 
CLSI standard procedures (12). Susceptibility 
to imipenem (10 μg), meropenem (10 μg), te-
tracycline (30 μg), chloramphenicol (30 μg) and 
sulphametoxazole /trimethoprim (23.75 /1.25 μg) 
was performed by disk diffusion test (12).
Phenotypic detection of ESBLs and plasmid-
mediated AmpC ß-lactamases
A double-disk-synergy test (DDST) using the 
combination of amoxycillin/clavulanate with 
cefotaxime, ceftriaxone, ceftazidime, and cefe-
pime was performed to detect the production of 
ESBLs. Distortion of the inhibition zones around 
cephalosporin and aztreonam disks towards cen-
tral disk was considered as a positive result (14). 
Production of ESBLs was confirmed by CLSI 
combined disk test. 
Production of plasmid-mediated AmpC 
β-lactamase was tested in E. coli, Klebsiella spp. 
and P. mirabilis by combined disk test using 
3-amino phenyl boronic acid. An overnight Mu-
eller-Hinton (MH) broth culture of the strains 
was adjusted and swabbed on MH agar and disks 
of cefotaxime, ceftriaxone, ceftazidime and cefe-
pime were placed on the surface of the agar plate. 
10 µl of  3-amino phenyl boronic acid (20 mg/
mL) was  dropped on the disks containing cefo-
taxime (30 µg), ceftriaxone (30 µg), ceftazidime 
(30 µg) and cefepime (30 µg). Control plate con-
tained disks of the same cephalosporins without 
phenyl boronic acid. Augmentation of the inhi-
bition  zones around cephalosporin disks for ≥ 5 
mm in the presence of boronic acid was indica-
tive for production of AmpC β-lactamases (15).
Transfer of resistance determinants
The transferability of cefotaxime resistance was 
tested by conjugation (broth mating method). 
Enterobacteriaceae were investigated for the 
transferability of their resistance determinants. 
Conjugation experiments were set up employing 
plasmid-free and rifampin-resistant E. coli A15 
R- recipient strain (15). Transconjugants were 
selected on the combined plates containing cefo-
taxime (1 mg/L) and rifampicin (256 mg/L). The 
frequency of conjugation was expressed relati-
vely to the number of donor cells. 
Typing of the spa locus of MRSA isolates 
Real-time amplification of the spa locus 
followed by sequencing was performed as des-
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cribed above (16). The spa types were cluste-
red into spa CCs (clonal complexes) using the 
algorithm based upon repeat pattern (BURP) 
with the Ridom Staph Type, version 1.5, 
software package (http://www.ridom.de) (17). 
The default settings recommended by the ma-
nufacturer were used. Since it has been shown 
that spa typing, together with the algorithm 
BURP, yields results consistent with typing 
results obtained by MLST (17-19), the asso-
ciated CCs, as determined with MLST, were 
allocated through the Ridom SpaServer (http://
spaserver.ridom.de).
Molecular characterization of ESBL and plasmid-
mediated AmpC ß-lactamases
PCR was used to detect alleles encoding ESBL 
enzymes. Extended-spectrum β-lactamases were 
characterized at the molecular genetic level. The 
presence of blaTEM, blaSHV, blaCTX-M, ESBL genes 
was investigated by polymerase chain reaction 
(PCR) using primers and conditions as descri-
bed previously (9,20,21). Template DNA was 
extracted by boiling method. PCR mix (50 µl) 
contained 25 µl of master mix (Roche), 20 µl of 
ultrapure water, 1 µl of each primer (10 pmol) 
and 3 µl of template DNA. Strains positive for 
CTX-M beta-lactamases were further tested by 
multiplex PCR with primers specific for CTX-
M groups 1, 2, 8, 9 and 25 (22). Amplicons were 
column-purified (Quiagen DNA purification kit) 
and sequenced directly using ABI PRISM 377 
Genetic Analyzer (Applied Biosystems). Sequ-
ences were analyzed using BioEdit v.7.0.9. (Ibis 
Biosciences) program. Designation of bla genes 
based on identified mutations was done accor-
ding to Bush and Jacoby (23).
Primers IS26F (5’-GCG-GTA-AAT-CGT-GGA-
GTG-AT-3) and IS26R (5’-ATT-CGG-CAA-
GTT-TTT-GCT-GT-3’) were used to amplify 
400 bp fragment spanning the link between 
IS26 insertion sequence and bla
CTX-M
 gene in 
CTX-M producing isolates (22). Primers ISEc-
p1L1 (CAGCTTTTATGACTCG) and ALA-5 
(CCTAAATTCCACGTGTGT) were applied to 
amplify the ISEcpI insertion sequence (10). 
Multiplex PCR with primers specific for MOX, 
CMY, DHA, and FOX β-lactamases was used 
to detect plasmid-mediated Amp β-lactamases 
in E. coli, Klebsiella spp. and P. mirabilis stra-
ins resistant to cefoxitin and β-lactam/inhibitor 
combinations (11).
Typing by pulsed-field gel electrophoresis (PFGE) 
of bacterial DNA
Isolation of genomic DNA, its digestion with 
the XbaI restriction enzyme (Invitrogen) and 
PFGE of the resulting fragments was perfor-
med as described by Kaufman et al. (24,25). 
The electrophoresis was carried out with a 
CHEF-DRII apparatus (Bio-Rad Laboratories, 
Hercules, CA). The PFGE patterns were com-
pared following the criteria of Tenover et al. 
(26) and analyzed by the GelComparII softwa-
re (Applied Maths, St Martens, Belgium). The 
patterns obtained were compared by clustering 
methods (unweighted pair group methods with 
arithmetic averages) using the Dice coefficient. 
The optimization of 0.5% and position toleran-
ce of 3% were applied.
RESULTS
During the period December 2009 – May 2010, 
33 hospitalized patients with SSTIs caused by 
MRSA or/and ESBL-producing Gram-negative 
bacteria were identified: 17 patients had infection 
caused by MRSA, 13 patients had infection cau-
sed by ESBL-producing Gram-negative bacteria, 
and three patients had co-infection with MRSA 
and ESBL-producers.
MRSA infections
Among 20 in-patients infected with MRSA, six 
(30%) had surgical wound infections (SWI) and 
14 (60%) had oSSTIs. Three patients with MRSA 
(two were spa-type t355) infection had co-infec-
tion with MSSA (one patient with oSST at Der-
matology, and two patients with SWI at surgery 
and orthopaedic department, respectively). Five 
(25%) in-patient and two (out of five) outpatient 
isolates were susceptible to all antibiotic tested, 
respectively. None of the isolates were multidrug-
resistant. Most in-patient isolates have shown 
gentamicin resistance phenotype, 13 (65.0%). 
In outpatient settings five SSTIs were noted, all 
were oSSTIs; one was MRSA MLST CC152 
(newborn). 
Among 14 oSSTIs, all but one MRSA belonged 
to spa-clonal-complex (CC) 355/595 associated 
with MLST CC152. Among six MRSA isolated 
Uzunović et al. MRSA and ESBL skin and soft tissue infections
Medicinski Glasnik, Volume 12, Number 2, August 2015
70
from SWIs, MLST CC152 was found in three ca-
ses (Table 1).
Most in-patients with MRSA SSTIs were ad-
mitted to the hospital from home, with an excep-
tion of five patients who were transferred from 
other hospital or from nursing home (four MRSA 
belonged to MLST CC152) (Table 1). All hos-
pitalized patients with SSTIs had contact with 
persons with positive history of hospitalization. 
A history of β-lactam antibiotics usage in combi-
nation with glycosides was positive in 16 patients 
(data not shown).
Protocol 
No Gender
Isolate 
origin
Age 
(years)
HospItal 
department
Spa-type
(Spa CC)
(MLST CC)
Residance 
before 
hospitali-
zation
Susceptibility/resistance to antimicrobial agents*
IMP ERY VAN GEN AMK CIP CLI SXT CHL RA MUP
3196 F oSSTI 42 Dermatology t355(355/595) (152) Home S S S R S S S NT NT S S
21441† M oSSTI 40 Dermatology t355(355/595) (152) Home NT S S R NT S S S S S S
245 F SWI 54 ICU t355(355/595) (152)
Other 
hospital S S S R S S S NT NT S S
13549 M SWI 60 Internal t1855(singleton) Home NT S S S NT S S S NT S S
13476 † F SWI 45 Orthopedics t041(002) (005)
Other 
hospital NT S S S NT S S S NT S S
4357 F oSSTI (um-bilicus) <01 Pediatrics
t355
(355/595) (152)
Health care 
center S S S S S S S NT NT S S
2236 M oSSTI 01 Pediatrics t355(355/595) (152)
Health care 
center S S S R S S S NT NT S S
17304 F oSSTI 01 Pediatrics t355(355/595) (152) Home NT S S S NT S S R S S S
2822 F oSSTI 01 Pediatrics t355(355/595) (152) Home S S S R S R S NT NT S S
33733 M oSSTI 01 Pediatrics t355(355/595) (152) Home NT S S R S S S S S S
4189 M oSSTI <01 Pediatrics t355(355/595) (152) Home S S S R S S S NT NT S S
39027 M oSSTI <01 Pediatrics t355(355/595) (152) Home NT S S R NT S S S S S S
8723 M oSSTI <01 Pediatrics t355(355/595) (152) Home S S S R S S S NT NT S S
5928 M oSSTI (um-bilicus) <01 Pediatrics
t355
(355/595) (152) Home S S S R S S S NT NT S S
9522 F oSSTI <01 Pediatrics t355(355/595) (152) Home S S S R S S S NT NT S S
25621 F oSSTI 02 Pediatrics t595(355/595) (152) Home NT S S R NT S S S S S S
16578 M oSSTI <01 Pediatrics t919(008/024) (008) Home NT S S S NT S S S S S S
26267 † F SWI 01 Surgery t355(355/595) (152) Home NT S S R NT S S S S S S
32913 M SWI <01 Surgery t355(355/595) (152)
Health care 
center NT S S R NT S S S S S S
129/U M SWI Urology t7250(singleton) Home S S S S S S S S S S
7559 M oSSTI 01 Outpatient t728(015) (045) DM S S S S S S S S S S S
13802 F oSSTI (um-bilicus) 01 Outpatient
t355
(355/595) (152) DM NT S S S NT S S S NT S S
20733 F oSSTI <01 Outpatient Not typeable DM NT R S R NT R S R S S S
33005 M oSSTI 29 Outpatient t451(008/024) (008) DM NT R S R NT S S R S S S
16548 M oSSTI 01 Outpatient Not typeable NT S S R NT S S S S S S
Table 1. Characteristics of patients with MRSA infections  and susceptibility /resistance to antibiotics
*IMP, imipenem (10 µg); ERY, erythromycin (15 µg); VAN, vancomycin (30 µg); GEN, gentamicin (10 µg), AMK, amikacin (30 µg); CIP, 
ciprofloxacin (5 µg); CLI, clindamycin (2 µg);  SXT, trimethoprim/sulfamethoxazole (25  µg); CHL, chloramphenicol (30 µg); RIF,. rifampicin (5 
µg);  MUP, mupirocin (100 µg); †Patients with MRSA  and ESBL-producing Gram-negative bacteria coinfection Spa- CC, spa clonal complex; 
MLST CC, MLST clonal complex; SWI, surgical wound infection; oSSTI, other skin and soft tissue infection (other than SWI); NT, not tested; 
DM, data missing;
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Among 23 MRSA strains analyzed by PFGE, 15 
(65.2%) belonged to the same clonal complex 
(Figure 1).
ESBL infections
Among 16 in-patients with infection caused by 
ESBL-producing Gram-negative bacteria two 
(12.5%) had SWI and 14 (87.5%) had oSSTI. 
Most oSSTI hospital infections were registered 
at pediatric department, nine (56.3%) (all were 
newborns). ESBL-producing Klebsiella spp. was 
the most frequently isolated Gram-negative bac-
teria, in 12 (75%) in-patients of which K. pneu-
monia was isolated in 11 cases. 
The total number of 18 outpatients were infected 
with ESBL-producing Gram-negative bacteria, 
of which 17 (94.4%) had SWI and one had oS-
STI. Two outpatients had co-infection with two 
Gram-negative bacteria (K. pneumoniae in both 
cases with K. pneumoniae and Pseudomonas ae-
ruginosa, respectively). Klebsiella spp. was the 
most isolated, in seven (38.9%) cases. The four 
in-patients were transferred from another hospi-
tal. Eleven (61.1%) outpatients were ≥60 years of 
age (Table 2). 
Almost all in-patient ESBL-producing Klebsiella 
spp. isolates were resistant to gentamicin. Resi-
stance to ciprofloxacin was noted in six Klebsie-
lla spp. from in-patients, and in four outpatients. 
Two E. coli isolates have shown high-level resi-
stance to almost all tested antibiotics. From one 
of these, MRSA was isolated too. All but one 
(Pseudomonas) isolates remained susceptible to 
carbapenems (Table 2).
Eight strains transferred cefotaxime resistance to 
E. coli recipient strains with frequency ranging 
from 10-7 to 10-4. Resistance to gentamicin,  te-
tracycline, chloramphenicol and cotrimoxazole 
was cotransferred alongside with cefotaxime re-
sistance in four strains (data not shown). 
Seven (out of 18, 38.9%) K. pneumoniae isolates 
(all were from the in-patients) yielded amplicons 
with primers specific for all three SHV, TEM-1 
and CTX-M group 1 β-lactamases, one of which 
Figure 1. Dendogram showing the genetic relatedness of the 23 MRSA isolates. Two groups were identified by PFGE typing (A and 
B) by using 80% similarity. Group A consisted of two, group B of 15 isolates and they appeared to be clonally related S, singleton; 
oSSTI, other skin and soft tissue infections; SWI, surgical wound infections; NT, non-typeable;
Uzunović et al. MRSA and ESBL skin and soft tissue infections
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Figure 2. Dendogram showing the genetic relatedness of the K. pneumoniae and Escherichia coli strains by PFGE typing. A) The clone 
A comprised four K. pneumoniae outpatient strains and the clone B comprised two outpatient strains using the 80% similarity; three 
strains from pediatric and one from surgery hospital units were allocated in dominant cluster A, which contained two subclusters; 
B) Two E. coli strains were clonally related with 90% similarity of their banding patterns and assigned to cluster A; one strain was 
singleton. SSTI, skin and soft tissue infection; SWI, surgical wound infection;
additionally produced plasmid-mediated AmpC 
β-lactamase. One of four E. coli (all from out-
patients) coproduced both TEM and CTX-M 
β-lactamase. In one Pseudomonas aeruginosa 
isolate VIM β-lactamase was found. CTX-M  be-
ta-lactamases were most prevalent with 13 posi-
tive isolates (K. pneumoniae, E. coli, E. cloacae, 
Proteus vulgaris), and in five cases they were 
accompanied by both TEM-1 and OXA-1 beta-
lactamase (Table 2). 
Insertion sequence IS26 was located upstream of 
bla
CTX-M
 gene in two Enterobacter cloacae strains 
(data not shown). 
PFGE typing of K. pneumoniae using the 80% 
breakpoint for clonal relatedness revealed domi-
nant cluster A which contained two subclusters: 
the clone A comprised 4 outpatient and the clone 
B two outpatient K. pneumoniae strains; three 
strains from pediatric and one from surgery hos-
pital units were allocated in the dominant cluster 
A (Figure 2 A). 
Two E. coli strains were clonally related with 
90% similarity of their banding patterns and assi-
gned to cluster A, and one strain was singleton 
(Figure 2 B). 
MRSA/ESBL coinfection
Among 17 and 16 in-patients with MRSA and 
ESBL infections, respectively, three patients 
were coinfected with both (Table 3).
DISCUSSION 
S. aureus  is a causative agent of large number 
of ambulatory healthcare visits for skin and soft 
tissue infections each year (6). The prevalence of 
MRSA-positive SSTIs has increasing trend, and 
up to 46-72% prevalence was noted (4,6,27,28). 
Of the SSTI cultures negative for MRSA, almost 
half are usually caused by methicillin-sensitive 
S. aureus (MSSA), 6% by gram-negative orga-
nisms, and 3%  infections are polymicrobial (6). 
The  Gram-negative ESBL producing bacteria 
were identified more commonly as a causative 
agent  of post-surgical than other skin and soft 
tissue infections (7), and both Escherichia coli 
and Klebsiella spp. are among the most frequent 
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Patient
Protocol 
No
Age 
(years)
Isolate origin
Hospital 
department
Causative agent
Residance 
before hospi-
talization
ATB used
Patient 1 13476
45
SWI Orthopedics MRSA (spa-type t041; spa-CC 002; MLST CC5)
Other hospital
Fluoroquinolones
2721 Other SSTI Orthopedics Proteus mirabilis (ESBL+) Glycosides
Patient 2 26267
<01
SWI Surgery MRSA (spa-type t355; spa-CC 355/595; MLST CC152)
Home
Beta lactam+beta 
lactamase inhibitors
22040 Other SSTI (umbilicus) Pediatrics
Enterobacter cloacae (TEM-1, CTX-M-15, 
SHV-1)
Glycosides, penicillins
Patient 3 21441
40 Other SSTI Dermatology
MRSA (spa-type t355; spa-CC 355/595; MLST 
CC152) Home Fluoroquinolones
21441 P.  aeruginosa  (VIM)
Table 3. Patients with MRSA and ESBL-producing Gram-negative bacteria  coinfection 
* Patient with MRSA-ESBL coinfection; SWI, surgical wound infection; Other SSTI, skin and soft tissue infection other than SWI; 
enterobacteria  producing ESBLs in these infec-
tions (7). Almost equal proportion of both SSTI 
caused by MRSA and MSSA was noted in this 
study (among 43 SSTIs identified during the stu-
dy period caused by Staphylococcus spp., 39.5% 
were infected with MRSA, 41.9% with MSSA, 
9.3% with S. epidermidis, and 9.3% of patients 
had co-infection with MRSA and MSSA) (Uzu-
nović S, unpublished data).
According to the results of  this study  ESBL-
producing  Gram-negative bacteria in outpatients 
were more frequently causative agents of SWIs, 
in contrast to the in-patients in which they more 
frequently caused other SSTIs. K. pneumoniae 
was dominant ESBL-producing pathogen  of the 
in-patient SSTIs in this study, while the causati-
ve agents obtained from outpatient SSTIs were 
much more heterogeneous. A co-infection in 
SSTIs occurred frequently, mainly with Pseu-
domonas aeruginosa and MRSA (7), as demon-
strated in this study. Moreover, two patients had 
co-infection with two ESBL-producing Gram-
negative bacteria. Chronic infections, especially 
in patients previously treated with antibiotics, 
tend to be polymicrobial. Such mixed infections 
additionally complicate the antibiotic treatment 
and the outcome (29).
Community-associated methicillin-resistant S. 
aureus (CA-MRSA) is the most common cause 
of SSTIs, especially in closed populations with 
frequent skin-to-skin contact (4,21). It is well 
known that skin infections occurred predomi-
nantly in children and young adults without risk 
factors, where family members can serve as a re-
servoir of CA-MRSA, so, the epidemic MRSA 
clone might be propagated in the community 
(30). As reported previously, an outbreak of CA-
MRSA infections in a neonatal intensive care 
unit was initiated by a mother with CA-MRSA 
wound infection and mastitis (31). In the present 
study,  it was not possible to differentiate betwe-
en hospital-associated MRSA (HA-MRSA) and 
CA-MRSA. However, we found that all patients 
with MRSA infection in this study had contacts 
with persons recently hospitalized  and who used 
antibiotics in the previous 4 months, which were 
identified as risk factors for HA-MRSA (6). Ba-
sed on antimicrobial susceptibility testing, MRSA 
in this study was susceptible to a wide range of 
antibiotics, which is typical for  CA-MRSA (27). 
From the genotyping results in this study, a MLST 
CC152 MRSA strains (Balkan clone) found in the 
in-patients (at multiple hospital departments),  as 
well as in the outpatients, suggesting clonal spre-
ad by cross-transmission following introduction 
in the hospital (32,33), which was previously 
described in other reports (31,34). Indeed, PFGE 
results have shown that 80% of the MRSA strains 
belonged to one clone. Similar to MRSA, ESBL-
producing K. pneumoniae were also clonally 
related indicating a common source. TEM- and 
SHV-type β-lactamases, mainly produced by K. 
pneumoniae, have spread throughout hospital 
settings, while CTX-M enzymes, mainly produ-
ced by E. coli, have become predominant in the 
community (35,36). ESBL-producing organisms 
are increasingly prevalent worldwide, and repre-
sent an emerging infectious threat, thus indica-
ting that ESBL-producing organisms may be an 
emerging problem not only in hospital, but also 
in outpatient settings (35-37). The gut coloniza-
tion of in-patients was identified as a risk factor 
for developing self and cross infections due to 
ESBL-producers, and further dissemination of 
ESBL-producing clones was a consequence of the 
transfer of patients between various units of the 
same hospital, but also between hospitals in the 
same countries, as well as across the borders (38). 
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MRSA colonization of patients or their house-
hold members represents an important risk for su-
bsequent MRSA infection (38). Nares and umbi-
licus were the two most common sites of MRSA 
colonization, and sampling of these two sites is 
necessary and might be adequate for surveillance 
cultures (24). Some authors suggest MRSA scre-
ening of family members, but others recommend 
the screening only for some categories of patients 
(40). Our study confirmed the importance of um-
bilicus as a possible site of the future infection 
and screening of mothers as possible sources of 
the future infection.
The three most commonly described groups of 
SSTIs are “other cellulitis or abscess”, “decubi-
tus ulcer” and “post-operation wound infection” 
(superficial infections), and they accounted for 
76.5% of all hospitalized cases (41), which is 
confirmed in this study.
The presence of MRSA and ESBL-producing or-
ganisms in outpatients  is a substantial concern, 
due to the high morbidity and mortality associated 
with possible consequent hospital infections and 
their emergence poses a significant threat (37).
There are some limitations of this study. Firstly, 
it could not be ascertained whether these SSTIs 
were community-acquired or healthcare-associa-
ted. Secondly, this retrospective report has been 
based on the results obtained in the 5-month peri-
od resulting in a small number of MRSA or ESBL-
producing bacteria causing SSTIs. Despite these 
shortcomings, this study underlines the importan-
ce of surveillance and  improving identification of 
MRSA and ESBL-producing bacteria in hospitals, 
as well as in community settings, not only in hos-
pitalized patients but in healthy people too.
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ABSTRACT
Cilj Istražiti meticilin-rezistentni S. aureus (MRSA) i gram-negativne bakterije koje proizvode ß-lakta-
maze proširenog spektra (ESBL) i plazmidom-posredovane AmpC ß-laktamaze kao uzročnike bolnič-
kih i vanbolničkih infekcija kože i mekih tkiva (SSTI).
Metode Osjetljivost na antibiotike određivana je disk-difuzijskom i mikrodilucijskom metodom u skla-
du s CLSI. MecA gen je određivan pomoću PCR-a, a genetička karakterizacija MRSA-e pomoću spa-
tipizacije i BURP-a (algorithm based upon repeat patterns). Dvostruki sinergistički disk-test korišten je 
za probir ESBLs. blaESBL aleli su detektirani pomoću PCR-a. Genetska srodnost između sojeva testirana 
je pomoću PFGE-a.
Rezultati Kod bolničkih pacijenata izolirano je 17 MRSA, 13 ESBL-producirajućih gram-negativnih 
bakterija, kod tri pacijenta zabilježena je koinfekcija obje bakterije, a kod vanbolničkih pacijenata pet 
MRSA i 16 ESBL-producirajućih gram-negativnih bakterija. Klebsiella spp. izolirana je u 11 bolničkih 
i sedam vanbolničkih pacijenata. MLST CC152 bio je najprevalentniji MRSA. Kod sedam (38,9%) 
Klebsiella spp. detektirani su amplikoni s početnicama specifičnim za SHV, TEM-1 i CTX-M grupu 1 
β-laktamaza. Osam (44,4%) sojeva K. pneumonia i 16 (64%) MRSA (bolničkih i vanbolničkih) pripa-
dali su klonovima. 
Zaključak MRSA i ESBL-producirajuće gram-negativne bakterije koje uzrokuju infekcije kože i me-
kih tkiva vrijedne su pažnje zbog toga što usljed visokog morbiditeta i mortaliteta predstavljaju  rizik 
za nastanak bolničkih infekcija. 
Ključne riječi: infekcije kirurških rada, CTX-M beta-laktamaze, MLST CC152, otpornost na antibio-
tike
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